Liquid-chromatographic assay of cefamandole in serum, urine, and dialysis fluid

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We describe a 'high-performance' liquid-chromatographic assay for quantifying cefamandole in biological fluids from patients with renal impairment. Serum samples are deproteinized with acetonitrile, then extracted with dichloromethane; dialysis-fluid samples are injected directly; urine samples are diluted appropriately before injection onto the reversed-phase column. The mobile phase is a methanol/aqueous solution (31/69 by vol) containing 500 μL of phosphoric acid, 20 mmol of sodium sulfate, and 200 μL of triethylamine per liter, the mixture being adjusted to pH 6.0 with NaOH. Retention time for cefamandole is 12 min. Its peak is well resolved in highly contaminated samples from renally impaired subjects. The assay's selectivity, reproducibility (within-day and between-day CVs <8% in all three sample fluids), and sensitivity - 0.5 mg/L in serum, 1.0 mg/L in dialysis fluid, and 5.0 mg/L in urine - make it applicable to pharmacokinetic studies.

Original languageEnglish (US)
Pages (from-to)197-200
Number of pages4
JournalClinical Chemistry
Volume32
Issue number1
StatePublished - 1986

Fingerprint

Cefamandole
Dialysis
Assays
Urine
Fluids
Methylene Chloride
Liquids
Serum
Methanol
Pharmacokinetics
Kidney
Injections
acetonitrile
sodium sulfate
triethylamine
phosphoric acid

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Liquid-chromatographic assay of cefamandole in serum, urine, and dialysis fluid. / Bliss, M.; Mayersohn, Michael.

In: Clinical Chemistry, Vol. 32, No. 1, 1986, p. 197-200.

Research output: Contribution to journalArticle

@article{dc490811a47e4bab869cad12f6a52187,
title = "Liquid-chromatographic assay of cefamandole in serum, urine, and dialysis fluid",
abstract = "We describe a 'high-performance' liquid-chromatographic assay for quantifying cefamandole in biological fluids from patients with renal impairment. Serum samples are deproteinized with acetonitrile, then extracted with dichloromethane; dialysis-fluid samples are injected directly; urine samples are diluted appropriately before injection onto the reversed-phase column. The mobile phase is a methanol/aqueous solution (31/69 by vol) containing 500 μL of phosphoric acid, 20 mmol of sodium sulfate, and 200 μL of triethylamine per liter, the mixture being adjusted to pH 6.0 with NaOH. Retention time for cefamandole is 12 min. Its peak is well resolved in highly contaminated samples from renally impaired subjects. The assay's selectivity, reproducibility (within-day and between-day CVs <8{\%} in all three sample fluids), and sensitivity - 0.5 mg/L in serum, 1.0 mg/L in dialysis fluid, and 5.0 mg/L in urine - make it applicable to pharmacokinetic studies.",
author = "M. Bliss and Michael Mayersohn",
year = "1986",
language = "English (US)",
volume = "32",
pages = "197--200",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - Liquid-chromatographic assay of cefamandole in serum, urine, and dialysis fluid

AU - Bliss, M.

AU - Mayersohn, Michael

PY - 1986

Y1 - 1986

N2 - We describe a 'high-performance' liquid-chromatographic assay for quantifying cefamandole in biological fluids from patients with renal impairment. Serum samples are deproteinized with acetonitrile, then extracted with dichloromethane; dialysis-fluid samples are injected directly; urine samples are diluted appropriately before injection onto the reversed-phase column. The mobile phase is a methanol/aqueous solution (31/69 by vol) containing 500 μL of phosphoric acid, 20 mmol of sodium sulfate, and 200 μL of triethylamine per liter, the mixture being adjusted to pH 6.0 with NaOH. Retention time for cefamandole is 12 min. Its peak is well resolved in highly contaminated samples from renally impaired subjects. The assay's selectivity, reproducibility (within-day and between-day CVs <8% in all three sample fluids), and sensitivity - 0.5 mg/L in serum, 1.0 mg/L in dialysis fluid, and 5.0 mg/L in urine - make it applicable to pharmacokinetic studies.

AB - We describe a 'high-performance' liquid-chromatographic assay for quantifying cefamandole in biological fluids from patients with renal impairment. Serum samples are deproteinized with acetonitrile, then extracted with dichloromethane; dialysis-fluid samples are injected directly; urine samples are diluted appropriately before injection onto the reversed-phase column. The mobile phase is a methanol/aqueous solution (31/69 by vol) containing 500 μL of phosphoric acid, 20 mmol of sodium sulfate, and 200 μL of triethylamine per liter, the mixture being adjusted to pH 6.0 with NaOH. Retention time for cefamandole is 12 min. Its peak is well resolved in highly contaminated samples from renally impaired subjects. The assay's selectivity, reproducibility (within-day and between-day CVs <8% in all three sample fluids), and sensitivity - 0.5 mg/L in serum, 1.0 mg/L in dialysis fluid, and 5.0 mg/L in urine - make it applicable to pharmacokinetic studies.

UR - http://www.scopus.com/inward/record.url?scp=0022917527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022917527&partnerID=8YFLogxK

M3 - Article

C2 - 3940707

AN - SCOPUS:0022917527

VL - 32

SP - 197

EP - 200

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -